标题
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
作者
关键词
-
出版物
AMERICAN JOURNAL OF HEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2022-05-13
DOI
10.1002/ajh.26590
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice
- (2022) Sagar Lonial et al. Lancet Haematology
- Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
- (2022) Noopur S Raje et al. Lancet Haematology
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
- (2021) Philippe Moreau et al. LANCET ONCOLOGY
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients
- (2021) Thierry Facon et al. BLOOD
- Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
- (2021) Christie P. M. Verkleij et al. Blood Advances
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
- (2021) Saad Z Usmani et al. LANCET
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
- (2021) Philippe Moreau et al. LANCET ONCOLOGY
- Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update
- (2021) Arjun Lakshman et al. AMERICAN JOURNAL OF HEMATOLOGY
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
- (2021) Thierry Facon et al. LANCET ONCOLOGY
- Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
- (2021) Carlos Fernández de Larrea et al. Blood Cancer Journal
- Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination
- (2021) Evangelos Terpos et al. JAMA Oncology
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
- (2020) Peter M. Voorhees et al. BLOOD
- BiTEing the Tumor
- (2020) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- (2020) Meletios Dimopoulos et al. LANCET
- Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Multiple myeloma current treatment algorithms
- (2020) S. Vincent Rajkumar et al. Blood Cancer Journal
- International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
- (2020) María-Victoria Mateos et al. Blood Cancer Journal
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma
- (2019) Edward A. Stadtmauer et al. JOURNAL OF CLINICAL ONCOLOGY
- MAIA under the microscope — bringing trial design into focus
- (2019) Prashant Kapoor et al. Nature Reviews Clinical Oncology
- Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase 1/2 studies
- (2019) Sara Bringhen et al. HAEMATOLOGICA
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Surrogate endpoints in randomised controlled trials: a reality check
- (2019) Shaji Kumar et al. LANCET
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
- (2019) Jens Hillengass et al. LANCET ONCOLOGY
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
- (2019) Chad C. Bjorklund et al. LEUKEMIA
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement
- (2019) David Murray et al. Blood Cancer Journal
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) David S. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
- (2018) Sara Bringhen et al. LEUKEMIA
- Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance
- (2018) Arjun Lakshman et al. LEUKEMIA
- The multiple myelomas — current concepts in cytogenetic classification and therapy
- (2018) Shaji K. Kumar et al. Nature Reviews Clinical Oncology
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
- (2018) Robert A. Kyle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
- (2018) Arjun Lakshman et al. Blood Cancer Journal
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
- (2018) Meletios A Dimopoulos et al. LANCET
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
- (2017) Andrew L. Himelstein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
- (2017) H Goldschmidt et al. LEUKEMIA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey
- (2017) O Landgren et al. Blood Cancer Journal
- High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
- (2017) A Miller et al. Blood Cancer Journal
- Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
- (2017) J Hillengass et al. Blood Cancer Journal
- VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
- (2016) Philippe Moreau et al. BLOOD
- Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma - a phase II trial
- (2016) Ulrich J. M. Mey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Multiple myeloma—translation of trial results into reality
- (2016) Philippe Moreau et al. LANCET
- Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
- (2016) María-Victoria Mateos et al. LANCET ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Progress in Myeloma — A Monoclonal Breakthrough
- (2016) S. Vincent Rajkumar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Smoldering multiple myeloma
- (2015) S. V. Rajkumar et al. BLOOD
- Clinical course and prognosis of non-secretory multiple myeloma
- (2015) Sagar S. Chawla et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
- (2015) T Vu et al. Blood Cancer Journal
- Interpretation of cytogenetic results in multiple myeloma for clinical practice
- (2015) A M Rajan et al. Blood Cancer Journal
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
- (2014) P. Rodon et al. HAEMATOLOGICA
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey
- (2014) O Landgren et al. LEUKEMIA
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load
- (2013) Kai Neben et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
- (2013) S V Rajkumar et al. LEUKEMIA
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
- (2012) S. Kumar et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition
- (2012) Terry M. Therneau et al. MAYO CLINIC PROCEEDINGS
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
- (2011) M. Q. Lacy et al. BLOOD
- Approach to the treatment of multiple myeloma: a clash of philosophies
- (2011) S. V. Rajkumar et al. BLOOD
- Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
- (2011) A. Larocca et al. BLOOD
- Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
- (2011) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple myeloma and the road to personalised medicine
- (2011) Stephen J Russell et al. LANCET ONCOLOGY
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
- (2011) Amrita Krishnan et al. LANCET ONCOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy and the activity of pomalidomide on extramedullary myeloma
- (2011) K Detweiler Short et al. LEUKEMIA
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
- (2010) F. van Rhee et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
- (2010) Martin Hjorth et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
- (2010) Angela Dispenzieri et al. LANCET
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
- (2010) María-Victoria Mateos et al. LANCET ONCOLOGY
- Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial
- (2010) P Moreau et al. LEUKEMIA
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Reduced-intensity allogeneic transplantation for myeloma: reality bites
- (2009) A. K. Stewart BLOOD
- A monoclonal gammopathy precedes multiple myeloma in most patients
- (2009) B. M. Weiss et al. BLOOD
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- The molecular characterization and clinical management of multiple myeloma in the post-genome era
- (2009) Y Zhou et al. LEUKEMIA
- Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis
- (2009) O Landgren et al. LEUKEMIA
- Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant
- (2009) P N Hari et al. LEUKEMIA
- Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
- (2009) D Gutman et al. LEUKEMIA
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- (2009) C B Reeder et al. LEUKEMIA
- Treatment of Myeloma: Cure vs Control
- (2009) S. Vincent Rajkumar MAYO CLINIC PROCEEDINGS
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
- (2009) Shaji K. Kumar et al. MAYO CLINIC PROCEEDINGS
- Many facets of bortezomib resistance/susceptibility
- (2008) S. Kumar et al. BLOOD
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
- (2008) A Dispenzieri et al. LEUKEMIA
- Pathogenesis of myeloma bone disease
- (2008) G D Roodman LEUKEMIA
- VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
- (2008) M Pineda-Roman et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started